TIL Instil Bio, Inc.

Nasdaq instilbio.com


$ 19.00 $ -1.09 (-5.4 %)    

Friday, 17-Oct-2025 19:29:45 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 19.085
$ 20.00
$ 18.01 x 50
$ 22.50 x 100
$ 18.05 - $ 20.33
$ 10.80 - $ 44.50
87,429
na
128.84M
$ 3.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-04-2025 01-01-1970 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-07-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-125-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price ta...

 instil-bio-says-immuneonco-biopharma-presents-preliminary-efficacy-and-safety-data-of-2510-as-monotherapy-in-phase-1-study-of-patients-in-china-with-previously-treated-sq-nsclc-at-2025-wclc

ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scoresDifferentiated structure of ‘251...

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-125-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price ta...

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-125-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price ta...

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-125-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.

 jmp-securities-reiterates-market-perform-on-instil-bioto-market-perform

JMP Securities analyst Reni Benjamin reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Market Perform.

 hc-wainwright--co-maintains-buy-on-instil-bio-lowers-price-target-to-105

HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and lowers the price target fro...

 instil-bio-immuneonco-advance-lung-cancer-drug-2510-with-new-trials-in-china-and-us-plans-ahead

Instil Bio, Inc. (NASDAQ:TIL, ", Instil", ))) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, &#...

 instil-bio-q1-adj-eps-132-beats-259-estimate

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(2.59) by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION